Tango Therapeutics, Inc. (TNGX)
22.02
-0.33
(-1.48%)
USD |
NASDAQ |
Sep 02, 10:33
Tango Therapeutics Research and Development Expense (Annual) : 129.88M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 129.88M |
| December 31, 2024 | 143.92M |
| December 31, 2023 | 115.20M |
| Date | Value |
|---|---|
| December 31, 2022 | 105.91M |
| December 31, 2021 | 77.64M |
| December 31, 2020 | 49.99M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Revolution Medicines, Inc. | 978.68M |
| Erasca, Inc. | 92.85M |
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 3.976M |
| Summit Therapeutics, Inc. | 537.67M |